Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We have developed a method called 'dose meta-analysis' to summarise modern doses in breast cancer radiotherapy, and their variation according to patient and tumour factors.

The main life-threatening risks from breast cancer radiotherapy are heart disease, lung cancer and oesophageal cancer. These risks increase according to heart radiation dose, lung dose and oesophageal dose respectively. We have performed dose meta-analyses of heart dose, lung dose and oesophageal dose from modern breast cancer radiotherapy. These have shown which breast cancer radiotherapy regimens have the lowest risks of heart disease (Taylor 2015) lung cancer (Aznar 2018) and oesophageal cancer (Duane 2021)

Back to Benefits and Risks of Cancer Treatments home page